Status: Recruiting
Gene Therapy for Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa
A clinical trial of gene therapy for patients with X-linked retinitis pigmentosa (XLRP).
Participants needed: 18
Trial details
Phase: Early Phase 1Age: 8-45Biological sex: MaleType: InterventionalSponsor: Frontera TherapeuticsUpdated: May 24, 2023Locations: 2
Eligibility criteria
Not listed